Imagine a world where a fungus holds the key to fighting one of the most devastating diseases known to humanity: brain cancer. Sounds like science fiction, right? But it’s not. MIT chemists have just synthesized a fungal compound that could revolutionize the way we treat brain cancer, specifically a rare and aggressive form called diffuse midline glioma (DMG). This breakthrough, published in the Journal of the American Chemical Society, marks the first successful synthesis of verticillin A—a compound discovered over 50 years ago but long considered too complex to recreate in the lab. And this is the part most people miss: while verticillin A differs from its cousin compound by just two oxygen atoms, those tiny changes made its synthesis a monumental challenge. But here’s where it gets controversial: could this fungal-derived compound, once deemed too difficult to produce, now pave the way for a new era in cancer therapy? Let’s dive in.
For decades, verticillin A has intrigued scientists for its potential as an anticancer and antimicrobial agent. Fungi naturally produce it to fend off pathogens, but its intricate structure—packed with rings, stereogenic centers, and sensitive functional groups—has stumped chemists for years. In 2009, MIT professor Mohammad Movassaghi and his team synthesized a similar compound, (+)-11,11'-dideoxyverticillin A, which has 10 rings and eight stereogenic centers. Yet, verticillin A remained elusive. Why? Those two extra oxygen atoms made the molecule incredibly fragile, limiting the chemical transformations possible. As Movassaghi explains, ‘Those two oxygens greatly limit the window of opportunity… It makes the compound so much more fragile, so much more sensitive.’
The real game-changer came when the team realized the timing of their synthetic steps was off. By reordering the sequence and introducing key functional groups earlier in the process, they finally cracked the code. The synthesis begins with beta-hydroxytryptophan, an amino acid derivative, and involves 16 meticulous steps to ensure the correct stereochemistry. One of the most innovative moves? ‘Masking’ sensitive disulfide bonds to protect them during the dimerization process—a technique that allowed the team to join the molecule’s two identical fragments without causing breakdown. Movassaghi notes, ‘This dimerization stands out in terms of the complexity of the substrates… It’s a dense array of functional groups and stereochemistry.’
But the real excitement began when the team tested verticillin A derivatives against DMG, a pediatric brain cancer with limited treatment options. Here’s the kicker: the compounds were most effective against DMG cell lines with high levels of the protein EZHIP, a known player in DNA methylation. By interacting with EZHIP, the derivatives appear to increase DNA methylation, triggering programmed cell death in cancer cells. The most potent compounds? N-sulfonylated versions of verticillin A and its cousin, which are more stable thanks to the addition of sulfur and oxygen groups. As Movassaghi puts it, ‘The natural product itself is not the most potent, but it’s the natural product synthesis that brought us to a point where we can make these derivatives and study them.’
Now, the Dana-Farber team is taking this research to the next level, validating the mechanism of action and preparing to test the compounds in animal models. But here’s the bold question: Could this fungal compound, once too complex to synthesize, become the foundation for a targeted therapy that changes the landscape of brain cancer treatment? And what does this mean for the future of natural compounds in drug discovery? The research, funded by the National Institute of General Medical Sciences, the Ependymoma Research Foundation, and the Curing Kids Cancer Foundation, is just the beginning. As Jun Qi, senior author of the study, states, ‘We will fully evaluate the therapeutic potential of these molecules… We have also profiled our lead molecules in more than 800 cancer cell lines, and will be able to understand their functions more broadly in other cancers.’
So, what do you think? Is this the start of a new chapter in cancer research, or just another promising lead that may not pan out? Let us know in the comments—we’d love to hear your thoughts!
